Choosing/VBG
Optimal/JJ
STR/NN
Markers/NNS
for/IN
Quality/NN
Assurance/NN
of/IN
Distributed/JJ
Biomaterials/NNS
in/IN
Biobanking/JJ
./.
====================
The/DT
quality/NN
assurance/NN
(/(
QA/NN
)/)
is/VBZ
of/IN
utmost/JJ
importance/NN
in/IN
biobanks/NNS
when/WRB
archived/VBN
biomaterials/NNS
are/VBP
distributed/VBN
to/TO
biomedical/JJ
researchers/NNS
./.
====================
For/IN
sample/NN
authentication/NN
and/CC
cross-contamination/NN
detection/NN
,/,
the/DT
two/CD
fundamental/JJ
elements/NNS
of/IN
QA/NN
,/,
STR/NN
genotyping/VBG
is/VBZ
usually/RB
utilized/VBN
./.
====================
However/RB
,/,
the/DT
incorporated/VBN
number/NN
of/IN
STR/NN
markers/NNS
is/VBZ
highly/RB
redundant/JJ
for/IN
biobanking/VBG
purposes/NNS
,/,
resulting/VBG
in/IN
time/NN
and/CC
cost/JJ
inefficiency/NN
./.
====================
An/DT
index/NN
to/TO
measure/VB
the/DT
crosscontamination/NN
detection/NN
capability/NN
of/IN
an/DT
STR/NN
marker/NN
,/,
the/DT
mixture/NN
probability/NN
(/(
MP/NN
)/)
,/,
was/VBD
developed/VBN
./.
====================
MP/NN
as/IN
well/RB
as/IN
other/JJ
forensic/JJ
parameters/NNS
for/IN
STR/NN
markers/NNS
was/VBD
validated/VBN
using/VBG
STR/NN
genotyping/VBG
data/NNS
on/IN
2328/CD
normal/JJ
Koreans/NNS
with/IN
the/DT
commercial/JJ
AmpFlSTR/NN
kit/NN
./.
====================
For/IN
Koreans/NNS
,/,
7/CD
STR/NN
marker/NN
(/(
D2S1338/NN
,/,
FGA/NN
,/,
D18S51/NN
,/,
D8S1179/NN
,/,
D13S317/NN
,/,
D21S11/NN
,/,
vWA/NN
)/)
set/NN
was/VBD
sufficient/JJ
to/TO
provide/VB
discrimination/NN
power/JJR
of/IN
∼10−10/CD
and/CC
crosscontamination/NN
detection/NN
probability/NN
of/IN
∼1/NN
./.
====================
Interestingly/RB
,/,
similar/JJ
marker/NN
sets/NNS
were/VBD
obtained/VBN
from/IN
African/JJ
Americans/NNS
,/,
Caucasian/JJ
Americans/NNS
,/,
and/CC
Hispanic/JJ
Americans/NNS
under/IN
the/DT
same/JJ
level/NN
of/IN
discrimination/NN
power/JJR
./.
====================
Only/RB
a/DT
small/JJ
subset/NN
of/IN
commonly/RB
used/VBN
STR/NN
markers/NNS
is/VBZ
sufficient/JJ
for/IN
QA/NN
purposes/NNS
in/IN
biobanks/NNS
./.
====================
A/DT
procedure/NN
for/IN
selecting/VBG
optimal/JJ
STR/NN
markers/NNS
is/VBZ
outlined/VBN
using/VBG
STR/NN
genotyping/VBG
results/NNS
from/IN
normal/JJ
Korean/JJ
population/NN
./.
====================
Large/JJ
scale/NN
biomedical/JJ
researches/VBZ
aiming/VBG
at/IN
identifying/VBG
diagnostic/JJ
or/CC
therapeutic/JJ
markers/NNS
and/CC
recent/JJ
technological/JJ
advancements/NNS
in/IN
highthroughput/JJ
platforms/NNS
have/VBP
triggered/VBN
interests/NNS
in/IN
high/JJ
quality/NN
biomaterials/NNS
./.
====================
In/IN
particular/JJ
,/,
as/IN
the/DT
amount/NN
of/IN
required/VBN
biomaterials/NNS
for/IN
basic/JJ
researches/VBZ
on/IN
disease/NN
diagnostics/NNS
and/CC
treatment/NN
,/,
target/NN
identification/NN
and/CC
subsequent/JJ
validation/NN
is/VBZ
increasing/VBG
in/IN
an/DT
unprecedented/JJ
pace/NN
,/,
the/DT
need/JJ
for/IN
a/DT
stable/JJ
supply/RB
mechanism/NN
of/IN
reliable/JJ
biomaterials/NNS
is/VBZ
urgent/JJ
and/CC
biobanking/VBG
has/VBZ
attracted/VBN
a/DT
great/JJ
deal/JJ
of/IN
attention/NN
as/IN
a/DT
viable/JJ
solution/NN
./.
====================
By/IN
collecting/VBG
and/CC
storing/VBG
biomaterials/NNS
from/IN
large/JJ
numbers/NNS
of/IN
individuals/NNS
that/IN
can/MD
encompass/VB
a/DT
diverse/JJ
spectrum/NN
of/IN
socioeconomic/JJ
,/,
demographic/JJ
,/,
and/CC
epidemiological/JJ
characteristics/NNS
,/,
biobanks/VBZ
are/VBP
already/RB
making/VBG
great/JJ
impacts/VBZ
on/IN
various/JJ
epidemiological/JJ
researches/VBZ
and/CC
quite/RB
a/DT
few/JJ
biobanks/NNS
are/VBP
already/RB
up/IN
and/CC
running/JJ
world/NN
wide/JJ
(/(
Hakonarson/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Triendl/NNP
,/,
2003/CD
;/:
LifeGene/NNP
Sweden/JJ
;/:
Elliott/NNP
&/CC
Peakman/JJ
,/,
2008/CD
;/:
Bhak/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Ahn/NNP
,/,
2007/CD
)/)
./.
====================
Biobanks/NNS
require/VBP
high/JJ
standards/NNS
in/IN
every/DT
aspect/NN
of/IN
its/PRP$
usual/JJ
operation/NN
for/IN
quality/NN
assurance/NN
(/(
QA/NN
)/)
purposes/NNS
since/IN
poorly/RB
managed/VBN
biomaterials/NNS
or/CC
related/JJ
biomedical/JJ
information/NN
can/MD
do/VBP
only/RB
harm/VBP
./.
====================
It/PRP
is/VBZ
usually/RB
required/VBN
to/TO
standardize/VB
all/DT
necessary/JJ
steps/NNS
as/IN
much/RB
as/IN
possible/JJ
and/CC
document/VBP
them/PRP
as/IN
standard/JJ
operating/VBG
protocols/NNS
(/(
SOPs/NNS
)/)
in/IN
an/DT
unmistakable/JJ
way/NN
(/(
Troyer/NN
,/,
2008/CD
)/)
./.
====================
Many/JJ
biobanks/NNS
are/VBP
currently/RB
in/IN
an/DT
establishment/NN
phase/NN
,/,
aiming/VBG
at/IN
collecting/JJ
and/CC
archiving/VBG
biomaterials/NNS
and/CC
their/PRP$
relevant/JJ
biomedical/JJ
information/NN
for/IN
future/JJ
use/NN
./.
====================
Owing/VBG
to/TO
this/DT
,/,
several/JJ
working/VBG
protocols/NNS
of/IN
sample/JJ
collection/NN
,/,
delivery/NN
,/,
processing/NN
,/,
storage/NN
,/,
and/CC
retrieval/JJ
are/VBP
available/JJ
for/IN
reference/NN
purposes/NNS
(/(
International/NNP
Society/NN
for/IN
Biological/JJ
Environmental/JJ
Respositories/NNS
2008/CD
;/:
Elliott/NN
and/CC
Peakman/JJ
,/,
2008/CD
)/)
./.
====================
However/RB
,/,
the/DT
ultimate/JJ
goal/NN
of/IN
a/DT
biobank/NN
is/VBZ
to/TO
make/VB
the/DT
general/JJ
access/VBP
of/IN
researchoriented/JJ
people/NN
to/TO
high/JJ
quality/NN
biomaterials/NNS
possible/JJ
with/IN
minimal/JJ
efforts/NNS
./.
====================
This/DT
requires/VBZ
an/DT
optimized/VBN
procedure/NN
for/IN
sample/NN
distribution/NN
and/CC
proper/JJ
measures/NNS
of/IN
QA/NN
for/IN
archived/JJ
biomaterials/NNS
./.
====================
For/IN
instance/NN
,/,
when/WRB
genomewide/VBN
association/NN
studies/NNS
which/WDT
usually/RB
require/VBP
tens/NNS
of/IN
thousands/DT
of/IN
high/JJ
quality/NN
DNA/NN
samples/NNS
in/IN
a/DT
short/JJ
period/NN
of/IN
time/NN
are/VBP
underway/RB
,/,
providing/VBG
them/PRP
with/IN
a/DT
proper/JJ
level/NN
of/IN
QA/NN
in/IN
the/DT
required/VBN
time/NN
frame/NN
can/MD
be/VB
a/DT
difficult/JJ
task/NN
./.
====================
QA/DT
of/IN
biomaterials/NNS
in/IN
biobanks/NNS
raises/VBZ
two/CD
issues/NNS
:/:
to/TO
authenticate/VB
that/DT
the/DT
specimen/NN
in/IN
a/DT
container/NN
matches/NNS
exactly/RB
the/DT
participant/JJ
that/IN
can/MD
be/VB
identified/VBN
by/IN
the/DT
label/JJ
on/IN
it/PRP
and/CC
to/TO
avoid/VB
crosscontamination/NN
of/IN
biomaterials/NNS
from/IN
different/JJ
donors/NNS
./.
====================
Any/DT
of/IN
these/DT
QA/NN
breaches/NNS
can/MD
mislead/VB
or/CC
nullify/JJ
the/DT
research/NN
results/NNS
in/IN
crucial/JJ
ways/NNS
./.
====================
Although/IN
efforts/NNS
to/TO
automate/VB
all/DT
or/CC
parts/NNS
of/IN
biobanking/VBG
processes/NNS
with/IN
the/DT
help/NN
of/IN
high/JJ
precision/NN
machines/NNS
are/VBP
going/VBG
on/IN
(/(
Downey/NNP
and/CC
Peakman/JJ
,/,
2008/CD
;/:
McQuillan/NNP
and/CC
Sales/NNS
,/,
2008/CD
;/:
Owen/RB
,/,
2008/CD
;/:
Fagan/NNP
and/CC
Ball/NNP
,/,
2008/CD
)/)
,/,
human/JJ
operations/NNS
still/RB
comprise/RB
many/JJ
integral/JJ
portions/NNS
,/,
posing/VBG
the/DT
risk/NN
of/IN
unpredictable/JJ
quality/NN
problems/VBZ
during/IN
ordinary/JJ
operations/NNS
./.
====================
Subsequently/RB
,/,
there/EX
should/MD
be/VB
a/DT
proper/JJ
safeguard/JJ
to/TO
detect/VB
sample/NN
authentication/NN
problems/VBZ
or/CC
cross/JJ
contamination/NN
events/NNS
prior/JJ
to/TO
sample/JJ
distribution/NN
,/,
preventing/VBG
the/DT
utilization/NN
of/IN
non-quality-compliant/JJ
samples/NNS
and/CC
,/,
eventually/RB
,/,
erroneous/JJ
or/CC
null-discoveries/NNS
./.
====================
As/IN
a/DT
biobank/NN
providing/VBG
high/JJ
quality/NN
DNAs/NNS
for/IN
several/JJ
genome-wide/NN
association/NN
studies/NNS
on/IN
Koreans/NNS
,/,
our/PRP$
team/JJ
has/VBZ
collected/VBN
DNAs/NNS
from/IN
＞123,000/CD
general/JJ
Koreans/NNS
(/(
age/NN
＞40/CD
)/)
since/IN
year/NN
2001/CD
and/CC
has/VBZ
been/VBN
performing/VBG
short/JJ
tandem/JJ
repeat/NN
(/(
STR/NN
)/)
genotyping/VBG
for/IN
QA/NN
purposes/NNS
./.
====================
In/IN
particular/JJ
,/,
we/PRP
have/VBP
used/VBN
the/DT
commercially/RB
available/JJ
AmpFlSTR/NN
kit/NN
composed/VBN
of/IN
15/CD
autosomal/JJ
and/CC
one/CD
sex/NN
chromosomal/JJ
STR/NN
markers/NNS
prior/JJ
to/TO
sample/JJ
distribution/NN
./.
====================
Based/VBN
on/IN
the/DT
core/NN
STR/NN
markers/NNS
from/IN
the/DT
combined/JJ
DNA/NN
index/NN
system/NN
(/(
CODIS/NNS
)/)
,/,
the/DT
STR/NN
panel/NN
works/NNS
superb/VBP
for/IN
various/JJ
jobs/NNS
requiring/VBG
individual/JJ
identification/NN
such/JJ
as/IN
forensics/VBZ
,/,
mass/NN
victim/RB
identification/NN
,/,
and/CC
paternity/NN
testing/VBG
(/(
Jobling/JJ
and/CC
Gill/RB
,/,
2004/CD
;/:
Ballantyn/NNP
,/,
1997/CD
;/:
Alford/RB
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
For/IN
instance/NN
,/,
the/DT
chance/NN
of/IN
two/CD
random/JJ
individuals/NNS
having/VBG
the/DT
same/JJ
STR/NN
typing/NN
profile/NN
is/VBZ
∼10−17/CD
in/IN
many/JJ
ethnic/JJ
populations/NNS
(/(
Kim/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
However/RB
,/,
we/PRP
think/VBP
this/DT
level/NN
of/IN
performance/NN
is/VBZ
too/RB
redundant/JJ
for/IN
QA/NN
in/IN
biobanks/NNS
./.
====================
As/IN
for/IN
the/DT
Korea/NN
biobank/NN
,/,
for/IN
instance/NN
,/,
which/WDT
is/VBZ
aiming/VBG
at/IN
collecting/JJ
biomaterials/NNS
from/IN
∼300,000/CD
participants/NNS
,/,
the/DT
appropriate/JJ
level/NN
of/IN
discrimination/NN
power/JJR
can/MD
be/VB
10−7/CD
when/WRB
100fold/RB
redundancy/NN
is/VBZ
assumed/VBN
or/CC
10−8/CD
when/WRB
1000fold/RB
redundancy/NN
is/VBZ
assumed/VBN
./.
====================
Under/IN
this/DT
premise/JJ
,/,
it/PRP
is/VBZ
obvious/JJ
that/DT
all/DT
15/CD
autosomal/JJ
markers/NNS
are/VBP
not/RB
required/VBN
and/CC
,/,
by/IN
incorporating/VBG
smaller/JJR
number/NN
of/IN
highly/RB
polymorphic/JJ
STR/NN
markers/NNS
in/IN
an/DT
optimized/VBN
way/NN
,/,
cost/RB
and/CC
time/NN
required/VBN
for/IN
QA/NN
can/MD
be/VB
greatly/RB
reduced/VBD
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
will/MD
introduce/VB
a/DT
general/JJ
strategy/NN
to/TO
select/VB
optimal/JJ
STR/NN
markers/NNS
to/TO
be/VB
adopted/VBN
in/IN
sample/JJ
authentication/NN
and/CC
in/IN
detecting/VBG
sample/NN
cross-contamination/NN
prior/JJ
to/TO
distribution/NN
and/CC
illustrate/VBP
it/PRP
using/VBG
our/PRP$
own/JJ
STR/NN
genotyping/VBG
results/NNS
./.
====================
Blood/NN
samples/NNS
were/VBD
collected/VBN
from/IN
Korea/NN
university/NN
Asan/NN
hospital/JJ
and/CC
Ajou/FW
University/NN
hospital/JJ
in/IN
Seoul/JJ
,/,
Korea/NN
./.
====================
Informed/VBN
consents/NNS
were/VBD
obtained/VBN
from/IN
all/DT
subjects/NNS
./.
====================
2328/CD
Koreans/NNS
that/DT
did/VBD
not/RB
have/VB
any/DT
apparent/JJ
disease-related/JJ
symptoms/NNS
were/VBD
recruited/VBN
in/IN
this/DT
study/NN
./.
====================
Genomic/JJ
DNA/NN
amplification/NN
was/VBD
carried/VBN
out/RP
using/VBG
about/RB
1.0ng/CD
of/IN
DNA/NN
for/IN
PCR/NN
amplification/NN
./.
====================
15/CD
STR/NN
loci/NNS
were/VBD
coamplified/VBN
with/IN
the/DT
AmpFlSTR1/NN
IdentifierTM/NN
PCR/NN
Amplification/NN
Kit/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
All/DT
amplifications/NNS
were/VBD
done/VBN
on/IN
a/DT
GeneAmp/NN
9700PCR/NN
system/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
Detection/NN
and/CC
genotyping/VBG
of/IN
PCR/NN
products/NNS
were/VBD
carried/VBN
out/RP
on/IN
the/DT
ABI/NN
PRISM/NN
3100/CD
DNA/NN
Analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
Division/PerkinElmer/NN
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
Electrophoresis/NN
results/NNS
were/VBD
analyzed/VBN
by/IN
Genemapper/NN
v3.1/NN
software/JJ
./.
====================
Allele/DT
and/CC
genotype/NN
frequencies/NNS
were/VBD
calculated/VBN
using/VBG
the/DT
gene/NN
counting/NN
algorithm/NN
./.
====================
Forensic/JJ
parameters/NNS
such/JJ
as/IN
matching/VBG
probability/NN
(/(
MP/NN
)/)
(/(
Brenner/NNP
and/CC
Morris/NNP
,/,
1990/CD
)/)
,/,
power/RB
of/IN
exclusion/NN
(/(
PE/NN
)/)
(/(
Brenner/NNP
and/CC
Morris/NNP
,/,
1990/CD
)/)
,/,
power/RB
of/IN
discrimination/NN
(/(
PD/NN
)/)
(/(
Jones/NNS
,/,
1972/CD
)/)
,/,
probability/NN
of/IN
identity/NN
(/(
PI/NN
)/)
(/(
Waits/NNS
et/FW
al./FW
,/,
2001/CD
)/)
,/,
polymorphic/JJ
information/NN
content/JJ
(/(
PIC/NN
)/)
(/(
Botstein/NNP
et/FW
al./FW
,/,
1980/CD
)/)
,/,
observed/VBN
heterozygosity/NN
(/(
H/NN
)/)
,/,
expected/VBN
heterozygosity/NN
(/(
HET/NNP
)/)
(/(
Nei/NNP
,/,
1987/CD
)/)
,/,
and/CC
the/DT
deviation/NN
from/IN
the/DT
HardyWeinberg/JJ
equilibrium/NN
(/(
HWE/NNP
)/)
(/(
Guo/NNP
and/CC
Thompson/NNP
,/,
1992/CD
)/)
were/VBD
calculated/VBN
./.
====================
The/DT
HWE/NN
was/VBD
further/RBR
validated/VBN
using/VBG
the/DT
Arlequin/NN
package/NN
(/(
Excoffier/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
The/DT
STR/NN
marker/NN
specific/JJ
probability/NN
to/TO
identify/VB
crosscontamination/NN
of/IN
biomaterials/NNS
from/IN
two/CD
donors/NNS
is/VBZ
calculated/VBN
as/IN
follows/VBZ
./.
====================
When/WRB
a/DT
sample/JJ
is/VBZ
mixed/VBN
with/IN
biomaterials/NNS
from/IN
two/CD
donors/NNS
in/IN
approximately/RB
equal/JJ
amounts/NNS
,/,
＞2/NN
peaks/VBZ
will/MD
appear/VBP
in/IN
the/DT
genotyping/VBG
result/NN
only/RB
when/WRB
the/DT
genotypes/NNS
from/IN
two/CD
donors/NNS
are/VBP
not/RB
identical/JJ
./.
====================
Let/NN
represent/VBP
the/DT
probability/NN
that/DT
one/CD
donor/NN
’/CD
s/NNS
genotype/NN
is/VBZ
given/VBN
by/IN
for/IN
a/DT
specific/JJ
marker/NN
./.
====================
Since/IN
we/PRP
are/VBP
dealing/VBG
with/IN
genotypes/NNS
whose/WP$
parental/JJ
origins/NNS
are/VBP
uncertain/JJ
,/,
we/PRP
assume/VBP
without/IN
loss/NN
of/IN
generality/NN
./.
====================
Then/RB
,/,
the/DT
mixture/NN
probability/NN
(/(
MP/NN
)/)
which/WDT
is/VBZ
the/DT
probability/NN
that/DT
a/DT
marker/NN
can/MD
detect/VB
crosscontamination/NN
from/IN
two/CD
different/JJ
donors/NNS
is/VBZ
given/VBN
by/IN
the/DT
equation/NN
./.
====================
If/IN
the/DT
marker/NN
does/VBZ
not/RB
violate/VB
the/DT
HWE/NN
,/,
this/DT
equation/NN
will/MD
be/VB
./.
====================
We/PRP
also/RB
performed/VBN
simulations/NNS
to/TO
validate/VB
the/DT
MPs/NNS
given/VBN
by/IN
Eq/NN
./.
====================
(/(
1/CD
)/)
or/CC
(/(
2/CD
)/)
using/VBG
our/PRP$
own/JJ
genotype/NN
results/NNS
./.
====================
From/IN
each/DT
marker/NN
’/CD
s/NNS
pool/NN
of/IN
genotypes/NNS
,/,
we/PRP
randomly/RB
selected/VBN
two/CD
genotypes/NNS
./.
====================
If/IN
the/DT
two/CD
genotypes/NNS
are/VBP
not/RB
identical/JJ
,/,
observed/VBN
mixture/NN
count/NN
is/VBZ
increased/VBN
by/IN
one/CD
./.
====================
Otherwise/JJ
,/,
it/PRP
is/VBZ
untouched/JJ
./.
====================
After/IN
performing/VBG
the/DT
random/JJ
selection/NN
process/NN
over/IN
times/NNS
,/,
the/DT
simulated/JJ
MP/NN
is/VBZ
calculated/VBN
by/IN
Actual/JJ
simulations/NNS
were/VBD
carried/VBN
out/RP
in/IN
a/DT
batch/JJ
mode/NN
:/:
we/PRP
calculated/VBD
the/DT
MS/NN
with/IN
and/CC
repeated/VBN
this/DT
procedure/NN
over/IN
20/CD
times/NNS
./.
====================
Then/RB
,/,
the/DT
average/NN
and/CC
standard/JJ
deviation/NN
of/IN
20/CD
MSs/NNS
are/VBP
reported/VBN
for/IN
each/DT
marker/NN
./.
====================
The/DT
forensic/JJ
parameters/NNS
and/CC
various/JJ
MPs/NNS
for/IN
15/CD
autosomal/JJ
STR/NN
markers/NNS
in/IN
AmpFlSTR/NN
kit/NN
for/IN
2328/CD
unrelated/JJ
normal/JJ
Koreans/NNS
are/VBP
provided/VBN
in/IN
Table/JJ
1/CD
./.
====================
Also/RB
,/,
full/JJ
results/NNS
including/VBG
allele/NN
frequencies/NNS
as/IN
well/RB
as/IN
parameters/NNS
shown/VBN
in/IN
Table/JJ
1/CD
are/VBP
provided/VBN
as/IN
a/DT
supplementary/JJ
material/JJ
./.
====================
When/WRB
all/DT
15/CD
autosomal/JJ
markers/NNS
are/VBP
utilized/VBN
,/,
the/DT
combined/JJ
PD/NN
,/,
PI/NN
,/,
and/CC
PE/NN
were/VBD
1.339×10−17/CD
,/,
1.169/CD
×10−17/CD
,/,
and/CC
0.999996/CD
,/,
respectively/RB
./.
====================
Since/IN
markers/NNS
are/VBP
independent/JJ
,/,
the/DT
collective/JJ
discrimination/NN
powers/NNS
were/VBD
calculated/VBN
by/IN
the/DT
product/NN
rule/JJ
./.
====================
The/DT
collective/JJ
discrimination/NN
power/JJR
indexes/NNS
illustrate/VBP
the/DT
highly/RB
polymorphic/JJ
nature/NN
of/IN
STR/NN
markers/NNS
in/IN
the/DT
AmpFlSTR/NN
panel/NN
;/:
these/DT
markers/NNS
provide/VBP
sufficient/JJ
differential/JJ
power/NN
for/IN
forensic/JJ
or/CC
paternity/NN
test/NN
purposes/NNS
./.
====================
It/PRP
is/VBZ
interesting/JJ
to/TO
note/VB
that/IN
HWE/NN
was/VBD
violated/VBN
in/IN
9/CD
markers/NNS
of/IN
our/PRP$
population/NN
(/(
D8S1179/CD
,/,
D7S820/NN
,/,
CSF1PO/NN
,/,
TH01/NN
,/,
D16S539/NN
,/,
D2S1338/NN
,/,
D19S433/NN
,/,
D18S51/NN
,/,
FGA/NN
)/)
./.
====================
This/DT
is/VBZ
not/RB
due/JJ
to/TO
any/DT
computational/JJ
artifacts/NNS
of/IN
our/PRP$
methodology/NN
adopted/JJ
in/IN
this/DT
study/NN
because/IN
similar/JJ
results/NNS
were/VBD
also/RB
obtained/VBN
from/IN
an/DT
independent/JJ
population/NN
genetics/NNS
package/NN
(/(
Nei/NNS
,/,
1987/CD
)/)
./.
====================
The/DT
exact/JJ
reason/NN
for/IN
this/DT
exotic/JJ
behavior/NN
,/,
however/RB
,/,
is/VBZ
not/RB
fully/RB
understood/VBN
yet/RB
./.
====================
As/IN
stated/VBN
in/IN
Introduction/NN
,/,
the/DT
level/NN
of/IN
collective/JJ
discriminative/JJ
power/JJR
of/IN
the/DT
commercial/JJ
kit/NN
is/VBZ
too/RB
redundant/JJ
for/IN
QA/NN
purposes/NNS
of/IN
usual/JJ
biobanks/VBZ
where/WRB
biomaterials/NNS
from/IN
∼105/CD
participants/NNS
are/VBP
to/TO
be/VB
archived/VBN
for/IN
the/DT
most/JJS
ambitious/JJ
cases/NNS
./.
====================
The/DT
optimal/JJ
set/NN
of/IN
STR/NN
markers/NNS
for/IN
QA/NN
can/MD
,/,
then/RB
,/,
be/VB
obtained/VBN
by/IN
recruiting/VBG
markers/NNS
of/IN
the/DT
best/JJS
discrimination/NN
power/JJR
recursively/RB
./.
====================
The/DT
number/NN
of/IN
optimal/JJ
markers/NNS
will/MD
be/VB
determined/VBN
by/IN
the/DT
number/NN
of/IN
markers/NNS
whose/WP$
collective/JJ
discrimination/NN
power/JJR
satisfies/NNS
the/DT
pre-specified/VBN
target/NN
value/NN
./.
====================
In/IN
Table/JJ
2/CD
,/,
we/PRP
listed/VBD
the/DT
cumulative/JJ
PD/NN
,/,
PI/NN
,/,
ME/NN
,/,
MH/NN
,/,
MS/NN
values/NNS
along/IN
STR/NN
markers/NNS
ranked/VBD
according/VBG
to/TO
their/PRP$
discrimination/NN
power/JJR
./.
====================
The/DT
STR/NN
markers/NNS
ranked/VBD
according/VBG
to/TO
their/PRP$
discrimination/NN
power/JJR
for/IN
Korean/JJ
population/NN
were/VBD
as/IN
follows/VBZ
:/:
D2S1338/NN
,/,
FGA/NN
,/,
D18S51/NN
,/,
D8S1179/NN
,/,
D13S317/NN
,/,
D21S11/NN
,/,
vWA/RB
,/,
D19S433/NN
,/,
D16S539/NN
,/,
D5S818/NN
,/,
D7S820/NN
,/,
CSF1PO/NN
,/,
D3S1358/NN
,/,
TH01/NN
,/,
TPOX/NN
./.
====================
The/DT
discrimination/NN
power/JJR
is/VBZ
determined/VBN
in/IN
principle/JJ
by/IN
the/DT
interplay/NN
between/IN
the/DT
number/NN
of/IN
admissible/JJ
alleles/NNS
of/IN
a/DT
marker/NN
and/CC
the/DT
homogeneity/NN
in/IN
allele/NN
frequency/NN
distributions/NNS
among/IN
admissible/JJ
alleles/NNS
./.
====================
Obviously/RB
,/,
a/DT
marker/NN
is/VBZ
not/RB
suitable/JJ
for/IN
sample/JJ
authentication/NN
or/CC
cross-contamination/NN
detection/NN
if/IN
it/PRP
has/VBZ
only/RB
a/DT
few/JJ
admissible/JJ
alleles/NNS
or/CC
all/DT
of/IN
its/PRP$
allele/NN
frequencies/NNS
are/VBP
condensed/VBN
in/IN
a/DT
small/JJ
number/NN
of/IN
alleles/NNS
./.
====================
For/IN
instance/NN
,/,
D2S1338/NN
which/WDT
possessed/VBD
the/DT
best/JJS
discrimination/NN
power/JJR
for/IN
Koreans/NN
required/VBN
6/CD
alleles/NNS
of/IN
the/DT
largest/JJS
frequency/NN
to/TO
cover/VB
80/CD
%/NN
of/IN
total/JJ
number/NN
of/IN
alleles/NNS
./.
====================
To/TO
the/DT
contrary/NN
,/,
TPOX/NN
which/WDT
possessed/VBD
the/DT
worst/NN
discrimination/NN
power/JJR
for/IN
Koreans/NN
required/VBN
only/RB
2/CD
alleles/NNS
of/IN
the/DT
largest/JJS
frequency/NN
to/TO
reach/VB
that/DT
level/NN
./.
====================
For/IN
the/DT
purpose/NN
of/IN
sample/JJ
authentication/NN
or/CC
cross/JJ
contamination/NN
detection/NN
,/,
top/NN
5∼7/CD
STR/NN
markers/NNS
are/VBP
enough/RB
for/IN
the/DT
Korea/NN
biobank/NN
according/VBG
to/TO
our/PRP$
results/NNS
in/IN
Table/JJ
2/CD
,/,
since/IN
the/DT
collective/JJ
individual/JJ
discrimination/NN
power/JJR
can/MD
be/VB
10−7∼10−10/CD
with/IN
this/DT
number/NN
of/IN
STR/NN
markers/NNS
./.
====================
This/DT
level/NN
of/IN
discrimination/NN
power/JJR
is/VBZ
100∼1,000/CD
times/NNS
redundant/JJ
for/IN
the/DT
target/NN
number/NN
of/IN
samples/NNS
to/TO
be/VB
recruited/VBN
for/IN
the/DT
Korea/NN
biobank/NN
./.
====================
For/IN
comparison/NN
,/,
the/DT
cumulative/JJ
marker/NN
performances/VBZ
of/IN
the/DT
same/JJ
STR/NN
markers/NNS
from/IN
AmpFlSTR/NN
kit/NN
for/IN
African/JJ
Americans/NNS
,/,
Caucasian/JJ
Americans/NNS
,/,
and/CC
Hispanic/JJ
Americans/NNS
are/VBP
detailed/VBN
in/IN
the/DT
supplementary/JJ
materials/NNS
(/(
Butler/NNP
,/,
2003/CD
)/)
./.
====================
With/IN
discrimination/NN
power/JJR
of/IN
10−10/CD
,/,
the/DT
optimal/JJ
marker/NN
sets/NNS
for/IN
Koreans/NN
,/,
African/JJ
Americans/NNS
,/,
Caucasian/JJ
Americans/NNS
,/,
and/CC
Hispanic/JJ
Americans/NNS
are/VBP
compared/VBN
in/IN
Table/JJ
3/CD
./.
====================
Interestingly/RB
,/,
optimal/JJ
marker/NN
sets/NNS
from/IN
the/DT
4/CD
ethnic/JJ
groups/NNS
were/VBD
almost/RB
similar/JJ
./.
====================
Sample/JJ
authentication/NN
and/CC
crosscontamination/NN
detection/NN
are/VBP
of/IN
utmost/JJ
importance/NN
for/IN
QA/NN
of/IN
biomaterials/NNS
archived/VBD
in/IN
biobanks/NNS
./.
====================
Owing/VBG
partly/RB
to/TO
the/DT
highly/RB
polymorphic/JJ
nature/NN
of/IN
STR/NN
markers/NNS
and/CC
partly/RB
to/TO
the/DT
availability/NN
of/IN
various/JJ
commercial/JJ
kits/NNS
making/VBG
the/DT
whole/JJ
process/NN
of/IN
genotyping/VBG
handy/NN
,/,
STR/NN
analysis/NN
lends/NNS
itself/PRP
as/IN
the/DT
de/FW
facto/FW
standard/JJ
approach/NN
for/IN
QA/NN
./.
====================
However/RB
,/,
the/DT
STR/NN
markers/NNS
in/IN
most/JJS
commercial/JJ
kits/NNS
are/VBP
highly/RB
redundant/JJ
for/IN
this/DT
purpose/NN
,/,
with/IN
excessive/JJ
combined/JJ
discrimination/NN
power/JJR
./.
====================
When/WRB
a/DT
biobank/NN
is/VBZ
designed/VBN
,/,
its/PRP$
sample/NN
collection/NN
target/NN
volume/NN
is/VBZ
first/JJ
set/NN
and/CC
,/,
subsequently/RB
,/,
the/DT
optimal/JJ
level/NN
of/IN
collective/JJ
discrimination/NN
power/JJR
can/MD
be/VB
specified/VBN
./.
====================
For/IN
instance/NN
,/,
when/WRB
the/DT
sample/NN
collection/NN
target/NN
number/NN
is/VBZ
set/NN
∼105/CD
level/NN
,/,
the/DT
optimal/JJ
level/NN
of/IN
discrimination/NN
power/JJR
can/MD
be/VB
10−7∼10−8/CD
,/,
allowing/VBG
for/IN
a/DT
level/NN
of/IN
redundancy/NN
100∼1,000/CD
fold/JJ
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
detailed/VBD
a/DT
strategy/NN
to/TO
select/VB
an/DT
optimal/JJ
STR/NN
marker/NN
set/NN
to/TO
allow/VB
the/DT
predetermined/JJ
target/NN
authentication/NN
power/JJR
with/IN
sufficient/JJ
level/NN
of/IN
crosscontamination/NN
detection/NN
power/JJR
at/IN
the/DT
same/JJ
time/NN
./.
====================
Although/IN
our/PRP$
study/NN
was/VBD
based/VBN
on/IN
genotyping/VBG
results/NNS
from/IN
a/DT
commercial/JJ
kit/NN
,/,
the/DT
strategy/NN
described/VBN
in/IN
our/PRP$
study/NN
is/VBZ
valid/JJ
in/IN
general/JJ
./.
====================
After/IN
setting/VBG
target/NN
levels/NNS
of/IN
collective/JJ
sample/NN
authentication/NN
and/CC
crosscontamination/NN
detection/NN
power/JJR
,/,
they/PRP
can/MD
choose/VB
an/DT
optimal/JJ
set/NN
of/IN
STR/NN
markers/NNS
simply/RB
by/IN
looking/VBG
at/IN
their/PRP$
forensic/JJ
parameters/NNS
and/CC
mixture/NN
probabilities/NNS
./.
====================
Of/IN
course/NN
after/IN
an/DT
optimal/JJ
set/NN
of/IN
STR/NN
markers/NNS
is/VBZ
selected/VBN
,/,
biobanks/VBZ
should/MD
optimize/VB
a/DT
genotyping/JJ
protocol/NN
so/RB
that/IN
high-throughput/VBP
QA/NN
can/MD
be/VB
achieved/VBN
on/IN
a/DT
regular/JJ
basis/NN
./.
====================
Utilizing/VBG
STR/NN
markers/NNS
from/IN
commercial/JJ
kits/NNS
can/MD
be/VB
advantageous/JJ
because/IN
they/PRP
are/VBP
already/RB
validated/VBN
for/IN
batch/NN
operations/NNS
and/CC
many/JJ
basic/JJ
statistical/JJ
characteristics/NNS
of/IN
them/PRP
are/VBP
possibly/RB
known/VBN
for/IN
the/DT
population/NN
of/IN
interest/NN
(/(
Butler/NNP
,/,
2006/CD
)/)
./.
====================
The/DT
sample/JJ
collection/NN
in/IN
biobanks/NNS
is/VBZ
usually/RB
carried/VBN
out/RP
by/IN
distributed/VBN
facilities/NNS
,/,
in/IN
which/WDT
case/NN
the/DT
quality/NN
control/NN
and/CC
maintenance/NN
of/IN
data/NNS
integrity/NN
can/MD
be/VB
a/DT
complicated/JJ
issue/NN
(/(
Troyer/NNP
,/,
2008/CD
)/)
./.
====================
When/WRB
the/DT
collection/NN
of/IN
large/JJ
number/NN
of/IN
blood/NN
samples/NNS
needs/VBZ
to/TO
be/VB
completed/VBN
in/IN
a/DT
timely/JJ
manner/NN
,/,
for/IN
instance/NN
,/,
the/DT
risk/NN
of/IN
confusing/VBG
participants/NNS
’/CD
identifiers/VBZ
and/CC
labels/NNS
on/IN
containers/NNS
or/CC
epidemiological/JJ
questionnaires/NNS
increases/VBZ
./.
====================
This/DT
risk/NN
will/MD
be/VB
greatly/RB
amplified/VBN
when/WRB
some/DT
samples/NNS
are/VBP
obtained/VBN
from/IN
new/JJ
participants/NNS
and/CC
generating/VBG
new/JJ
identifiers/NNS
will/MD
be/VB
enough/RB
for/IN
them/PRP
while/IN
others/NNS
are/VBP
obtained/VBN
from/IN
returning/VBG
participants/NNS
for/IN
follow-ups/NNS
where/WRB
existing/VBG
identifiers/VBZ
endowed/JJ
to/TO
participants/NNS
should/MD
be/VB
matched/VBN
exactly/RB
./.
====================
Furthermore/RB
,/,
when/WRB
a/DT
large/JJ
number/NN
of/IN
samples/NNS
are/VBP
processed/VBN
and/CC
important/JJ
biomaterials/NNS
like/IN
DNAs/NNS
are/VBP
fractionated/VBN
to/TO
multiple/JJ
small/JJ
volume/NN
tubes/NNS
for/IN
long/JJ
term/NN
storage/NN
,/,
the/DT
risk/NN
of/IN
cross-contamination/NN
will/MD
also/RB
increase/VBP
./.
====================
In/IN
fact/NN
,/,
there/EX
were/VBD
several/JJ
cases/NNS
of/IN
quality/NN
breach/NN
in/IN
the/DT
Korea/NN
Biobank/NN
identified/VBN
through/IN
STR/NN
genotypings/NNS
./.
====================
Some/DT
of/IN
the/DT
cases/NNS
were/VBD
traced/VBN
back/RB
to/TO
label/JJ
mixups/NNS
during/IN
blood/NN
subsampling/VBG
while/IN
other/JJ
cases/NNS
were/VBD
traced/VBN
back/RB
to/TO
cross/JJ
contaminations/NNS
during/IN
biomaterial/JJ
fractionations/NNS
./.
====================
Although/IN
the/DT
strict/JJ
adherence/NN
to/TO
established/JJ
SOPs/NNS
and/CC
the/DT
utilization/NN
of/IN
sophisticated/JJ
machineries/NNS
and/CC
information/NN
infrastructure/JJ
can/MD
reduce/VB
these/DT
risks/NNS
substantially/RB
,/,
any/DT
human/JJ
operations/NNS
by/IN
themselves/DT
pose/VBP
possible/JJ
risk/NN
of/IN
errors/NNS
./.
====================
As/IN
the/DT
final/JJ
safeguard/JJ
against/IN
such/JJ
unpredictable/JJ
risks/NNS
,/,
sample/NN
authentication/NN
and/CC
cross-contamination/NN
detection/NN
procedures/NNS
prior/JJ
to/TO
sample/JJ
distribution/NN
will/MD
be/VB
crucial/JJ
in/IN
practice/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
various/JJ
factors/NNS
that/WDT
could/MD
complicate/VB
the/DT
cross-contamination/NN
detection/NN
problem/NN
were/VBD
omitted/VBN
./.
====================
For/IN
instance/NN
,/,
we/PRP
assumed/VBD
that/IN
only/RB
two/CD
donors/NNS
contributed/VBD
their/PRP$
biomaterials/NNS
in/IN
approximately/RB
equal/JJ
amounts/NNS
./.
====================
Apparently/RB
,/,
this/DT
simplified/JJ
the/DT
whole/JJ
problem/NN
because/IN
,/,
in/IN
general/JJ
,/,
contributions/NNS
are/VBP
from/IN
＞2/CD
donors/NNS
with/IN
unequal/JJ
amounts/NNS
./.
====================
Since/IN
total/JJ
amount/NN
of/IN
biomaterials/NNS
is/VBZ
small/JJ
,/,
any/DT
transfer/NN
of/IN
foreign/JJ
biomaterials/NNS
during/IN
the/DT
procedure/NN
can/MD
hardly/RB
be/VB
undetected/VBN
./.
====================
Utilizing/VBG
commercial/JJ
kits/NNS
can/MD
be/VB
advantageous/JJ
in/IN
this/DT
case/NN
also/RB
because/IN
vendors/NNS
provide/VBP
ways/NNS
to/TO
estimate/VB
contributions/NNS
from/IN
different/JJ
donors/NNS
by/IN
comparing/VBG
allelic/JJ
peak/NN
amplitudes/VBZ
./.
====================
Supplementing/VBG
this/DT
information/NN
may/MD
make/VB
the/DT
whole/JJ
discussion/NN
more/RBR
thorough/IN
./.
====================
When/WRB
we/PRP
compared/VBD
the/DT
optimal/JJ
STR/NN
marker/NN
sets/NNS
from/IN
4/CD
ethnic/JJ
populations/NNS
(/(
Koreans/NNS
,/,
African/JJ
American/NN
,/,
Caucasian/JJ
American/NN
,/,
and/CC
Hispanic/JJ
Americans/NNS
)/)
under/IN
the/DT
same/JJ
level/NN
of/IN
discrimination/NN
power/JJR
(/(
10∼10/CD
)/)
,/,
they/PRP
were/VBD
almost/RB
identical/JJ
./.
====================
17/CD
In/IN
all/DT
ethnic/JJ
populations/NNS
,/,
the/DT
D2S1338/NN
marker/NN
provided/VBD
the/DT
most/JJS
optimal/JJ
performance/NN
and/CC
FGA/NN
and/CC
D18S51/NN
markers/NNS
provided/VBD
the/DT
next/JJ
optimal/JJ
performances/NNS
./.
====================
Beyond/CC
these/DT
markers/NNS
,/,
the/DT
exact/JJ
ranks/VBZ
of/IN
STR/NN
markers/NNS
were/VBD
slightly/RB
different/JJ
./.
====================
We/PRP
are/VBP
not/RB
so/RB
sure/NN
whether/IN
the/DT
same/JJ
universal/JJ
set/NN
of/IN
STR/NN
markers/NNS
can/MD
be/VB
utilized/VBN
in/IN
general/JJ
biobanks/NNS
regardless/RB
of/IN
their/PRP$
ethnic/JJ
background/NN
although/IN
our/PRP$
results/NNS
seem/VBP
to/TO
support/VB
the/DT
idea/NN
./.
====================
This/DT
obviously/RB
requires/VBZ
testing/VBG
our/PRP$
strategy/NN
in/IN
a/DT
lot/JJ
more/RBR
ethnic/JJ
populations/NNS
than/IN
we/PRP
did/VBD
in/IN
this/DT
study/NN
./.
====================
